Trial · NCT00006237

S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma

NCT00006237, Phase 3, Completed, SWOG Cancer Research Network; results first posted 2012-09-19

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma. Trials, record NCT00006237. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00006237

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma
NCT number: NCT00006237
Status: Completed
Phases: Phase 3
Enrollment: 432 participants, actual
Lead sponsor: SWOG Cancer Research Network
Conditions: Melanoma (Skin)
Interventions: interleukin-2, filgrastim, interferon alfa, cisplatin, dacarbazine, vinblastine
First posted: 2003-01-27
Last updated: 2015-03-25
Results first posted: 2012-09-19

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	5-year Overall Survival	Every three months for a year, every six months for years 2-5, annual for years 5-10	Overall survival was measured from the date of registration to study until death from any cause with observations censored at the date of last contact for patients last known to be alive.
Primary	5-year Relapse-Free Survival	Every three months for the first year, every 6 months for years 2-5, annually for years 6-10	Measured from date of registration to date of first observation of progressive disease or death due to any cause.
Secondary	Toxicity	While on treatment, patients on the HDIFN arm were assessed weekly for the 1st month, then every 2 weeks for the 2nd month, then every 3 months therafter; patients on the biochemo arm were assessed daily for the 1st 5 days, then weekly thereafter.	Number of patients with Grade 3-5 adverse events that are related to study drug by given type of adverse event

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	5-year Overall Survival	Every three months for a year, every six months for years 2-5, annual for years 5-10		Percent of population	NUMBER
PRIMARY	5-year Relapse-Free Survival	Every three months for the first year, every 6 months for years 2-5, annually for years 6-10		Percentage of population	NUMBER
SECONDARY	Toxicity	While on treatment, patients on the HDIFN arm were assessed weekly for the 1st month, then every 2 weeks for the 2nd month, then every 3 months therafter; patients on the biochemo arm were assessed daily for the 1st 5 days, then weekly thereafter.	Eligible patients who started therapy	Participants	NUMBER

Source ClinicalTrials.gov

Results by group186

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
5-year Overall Survival	Interferon		56	Percent of population
5-year Overall Survival	Biochemotherapy		56	Percent of population
5-year Relapse-Free Survival	Interferon		47	Percentage of population
5-year Relapse-Free Survival	Biochemotherapy		38	Percentage of population
Toxicity	Interferon	Abdominal pain/cramping	1	Participants
Toxicity	Biochemotherapy	Abdominal pain/cramping	1	Participants
Toxicity	Interferon	Acidosis	0	Participants
Toxicity	Biochemotherapy	Acidosis	1	Participants
Toxicity	Interferon	Acute vascular leak syndrome	0	Participants
Toxicity	Biochemotherapy	Acute vascular leak syndrome	1	Participants

1 to 10 of 186Source ClinicalTrials.gov

See all 186 results by group

Participant flow10

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Interferon	212
Overall Study	STARTED	Biochemotherapy	220
Overall Study	Eligible	Interferon	203
Overall Study	Eligible	Biochemotherapy	200
Overall Study	Eligible and Treated	Interferon	203
Overall Study	Eligible and Treated	Biochemotherapy	199
Overall Study	COMPLETED	Interferon	87
Overall Study	COMPLETED	Biochemotherapy	159
Overall Study	NOT COMPLETED	Interferon	125
Overall Study	NOT COMPLETED	Biochemotherapy	61

Source ClinicalTrials.gov

Adverse events62

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Anemia	Blood and lymphatic system disorders	Interferon	15	193
other	Anemia	Blood and lymphatic system disorders	Biochemotherapy	27	185
other	Diarrhea without colostomy	Gastrointestinal disorders	Interferon	13	193
other	Diarrhea without colostomy	Gastrointestinal disorders	Biochemotherapy	0	185
other	Nausea	Gastrointestinal disorders	Interferon	37	193
other	Nausea	Gastrointestinal disorders	Biochemotherapy	67	185
other	Vomiting	Gastrointestinal disorders	Interferon	23	193
other	Vomiting	Gastrointestinal disorders	Biochemotherapy	52	185
other	Fatigue/malaise/lethargy	General disorders	Interferon	79	193
other	Fatigue/malaise/lethargy	General disorders	Biochemotherapy	27	185

1 to 10 of 62Source ClinicalTrials.gov

See all 62 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Interferon
Total, all-cause mortality	Biochemotherapy
Total, other adverse events	Interferon	132	193
Total, other adverse events	Biochemotherapy	144	185
Total, serious adverse events	Interferon	2	193
Total, serious adverse events	Biochemotherapy	4	185

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
25332243	DERIVED

Source PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
U10CA032102	Southwest Oncology Group Treatment Grant	BLANKE, CHARLES D.	OREGON HEALTH & SCIENCE UNIVERSITY	NATIONAL CANCER INSTITUTE	1985 to 2013

Source NIH RePORTER

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Interferon vs Biochemotherapy: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00006237

GET https://conductscience.org/api/trials/v1/NCT00006237/results?page=2

API reference For AI assistants